Research·October 25, 2026 at 11:30 AM EDT·1 source
#ESMO26: AstraZeneca's Tagrisso-Orpathys combo may extend Tagrisso's life in lung cancer
AZN -0.6%
AZN · last 30 trading days-0.6% since the news
News
What happened
- AstraZeneca said the Tagrisso-Orpathys combination may help patients with mutant non-small cell lung cancer continue Tagrisso after developing resistance.
- The findings were presented at ESMO26 in Madrid, according to AstraZeneca.
Why it matters
The combination could affect treatment sequencing and the commercial life cycle of Tagrisso in mutant non-small cell lung cancer. Healthcare professionals will watch for additional efficacy and safety data.
Read more on YouBank
The Newsroom, ranked for your desk
About ninety free sources every ten minutes, one story per event, read for you: bankers, investors, operators and students each get their own desk. Free to start.
Timeline
- EarlierOct 22Roche talks up Phase 3 success rate as it unveils pipeline cuts
- EarlierOct 23China’s rapid human trials draw western drugmakers — and safety concerns
- EarlierYesterdayAmgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer
- EarlierYesterday#ESMO26: AstraZeneca eyes Keytruda's Padcev spot; Lilly's ADC takes on Elahere; Nubeqa targets earlier prostate cancer
- First reported by Endpoints News6h#ESMO26: AstraZeneca's Tagrisso-Orpathys combo may extend Tagrisso's life in lung cancer
Who is involved
#ESMO26: AstraZeneca's Tagrisso-Orpathys combo may extend Tag…AstraZenecaAZNTagrissoOrpathys
Company
Sources (1)
Related
- 4h · STAT+: At ESMO, AstraZeneca’s cancer pursuits get a showcase
- Yesterday · #ESMO26: AstraZeneca eyes Keytruda's Padcev spot; Lilly's ADC takes on Elahere; Nubeqa targets earlier prostate cancer
- Yesterday · Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer
- Oct 23 · China’s rapid human trials draw western drugmakers — and safety concerns
- Oct 22 · Roche talks up Phase 3 success rate as it unveils pipeline cuts
- Oct 20 · AstraZeneca Partners With Oracle to Refine Clinical Research With AI
Read more on YouBank
The Newsroom, ranked for your desk
About ninety free sources every ten minutes, one story per event, read for you: bankers, investors, operators and students each get their own desk. Free to start.
- Why it matters to youEvery story matched to your watchlist, your contacts and your pipeline.
- Follow developing storiesAn alert, and a push, the moment a story you follow moves.
- Your briefing, read aloudA few minutes each morning with a chapter per story.
- Brief modeSwipe through the day, a 20-second card each.